S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Day of Financial Reckoning Is Near (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
The Safest Option in Trades! (Ad)pixel
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
The Safest Option in Trades! (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Day of Financial Reckoning Is Near (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
The Safest Option in Trades! (Ad)pixel
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
The Safest Option in Trades! (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Day of Financial Reckoning Is Near (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
The Safest Option in Trades! (Ad)pixel
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
The Safest Option in Trades! (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Day of Financial Reckoning Is Near (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
The Safest Option in Trades! (Ad)pixel
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
The Safest Option in Trades! (Ad)pixel
NASDAQ:EPZM

Epizyme - EPZM Stock Forecast, Price & News

$1.47
0.00 (0.00%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.47
$1.47
50-Day Range
$0.54
$1.52
52-Week Range
$0.41
$5.80
Volume
N/A
Average Volume
3.36 million shs
Market Capitalization
$247.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Epizyme MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
104.1% Upside
$3.00 Price Target
Short Interest
Healthy
1.39% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.07
Upright™ Environmental Score
News Sentiment
0.82mentions of Epizyme in the last 14 days
Based on 15 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.36) to ($1.21) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.68 out of 5 stars

Medical Sector

98th out of 1,135 stocks

Pharmaceutical Preparations Industry

30th out of 557 stocks

EPZM stock logo

About Epizyme (NASDAQ:EPZM) Stock

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Epizyme Price Performance

Shares of NASDAQ:EPZM opened at $1.47 on Friday. Epizyme has a one year low of $0.41 and a one year high of $5.80. The business's fifty day moving average price is $1.25 and its 200-day moving average price is $1.12. The stock has a market capitalization of $247.50 million, a PE ratio of -0.85 and a beta of -0.41.

Epizyme (NASDAQ:EPZM - Get Rating) last announced its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.36) by $0.15. The business had revenue of $27.53 million for the quarter, compared to analyst estimates of $10.11 million. Epizyme had a negative return on equity of 2,459.33% and a negative net margin of 391.90%. As a group, equities analysts expect that Epizyme will post -1.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

EPZM has been the topic of several recent research reports. HC Wainwright lowered their price objective on Epizyme from $8.00 to $6.00 and set a "buy" rating on the stock in a research report on Friday, June 3rd. Wedbush cut Epizyme from an "outperform" rating to a "neutral" rating in a research report on Monday, June 27th. Cowen cut Epizyme from an "outperform" rating to a "market perform" rating and set a $1.50 price target on the stock. in a research report on Monday, June 27th. Cowen cut Epizyme from an "outperform" rating to a "market perform" rating and set a $1.50 price target on the stock. in a research report on Monday, June 27th. Finally, StockNews.com cut Epizyme from a "hold" rating to a "sell" rating in a research report on Monday, August 8th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $3.00.

Receive EPZM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Epizyme and its competitors with MarketBeat's FREE daily newsletter.

EPZM Stock News Headlines

Epizyme (NASDAQ:EPZM) Stock Rating Lowered by StockNews.com
Epizyme: Q2 Earnings Insights - Benzinga
Epizyme: Q2 Earnings Snapshot
Epizyme (NASDAQ:EPZM) Lifted to Hold at StockNews.com
Epizyme shares soar 60% on acquisition news
See More Headlines
Receive EPZM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Epizyme and its competitors with MarketBeat's FREE daily newsletter.

EPZM Company Calendar

Last Earnings
8/09/2022
Today
8/13/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EPZM
Employees
250
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+104.1%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$-251,120,000.00
Net Margins
-391.90%
Pretax Margin
-391.80%

Debt

Sales & Book Value

Annual Sales
$37.43 million
Book Value
($0.12) per share

Miscellaneous

Free Float
128,968,000
Market Cap
$247.50 million
Optionable
Optionable
Beta
-0.41

Key Executives

  • Mr. Grant C. Bogle (Age 64)
    Pres, CEO, Principal Financial Officer & Director
    Comp: $923.32k
  • Dr. Jeffery L. Kutok M.D. (Age 55)
    Ph.D., Chief Scientific Officer
    Comp: $646.13k
  • Dr. H. Robert Horvitz
    Co-Founder & Chairman of the Scientific Advisory Board
  • Dr. Yi Zhang
    Scientific Co-Founder & Member of The Scientific Advisory Board
  • Mr. Jerald Korn J.D. (Age 43)
    Chief Operating Officer
  • Mr. Joseph Beaulieu (Age 41)
    Sr. VP, Head of Fin., Controller, Treasurer & Principal Accounting Officer
  • Mr. Craig West CFA
    VP of Investor Relations
  • Mr. John F. Weidenbruch (Age 61)
    Sr. VP, Gen. Counsel & Sec.
  • Ms. Tanja Weber
    Chief Bus. Officer
  • Dr. Mark A. De Rosch Ph.D. (Age 58)
    Chief Regulatory Officer













EPZM Stock - Frequently Asked Questions

Should I buy or sell Epizyme stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" EPZM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EPZM, but not buy additional shares or sell existing shares.
View EPZM analyst ratings
or view top-rated stocks.

What is Epizyme's stock price forecast for 2022?

4 Wall Street research analysts have issued twelve-month price objectives for Epizyme's shares. Their EPZM share price forecasts range from $1.50 to $6.00. On average, they predict the company's share price to reach $3.00 in the next year. This suggests a possible upside of 104.1% from the stock's current price.
View analysts price targets for EPZM
or view top-rated stocks among Wall Street analysts.

How have EPZM shares performed in 2022?

Epizyme's stock was trading at $2.50 at the start of the year. Since then, EPZM shares have decreased by 41.2% and is now trading at $1.47.
View the best growth stocks for 2022 here
.

When is Epizyme's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our EPZM earnings forecast
.

How were Epizyme's earnings last quarter?

Epizyme, Inc. (NASDAQ:EPZM) issued its earnings results on Tuesday, August, 9th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.15. The biopharmaceutical company had revenue of $27.53 million for the quarter, compared to analysts' expectations of $10.11 million. Epizyme had a negative trailing twelve-month return on equity of 2,459.33% and a negative net margin of 391.90%.

What other stocks do shareholders of Epizyme own?

What is Epizyme's stock symbol?

Epizyme trades on the NASDAQ under the ticker symbol "EPZM."

Who are Epizyme's major shareholders?

Epizyme's stock is owned by a variety of institutional and retail investors. Top institutional investors include Primecap Management Co. CA (9.89%), Renaissance Technologies LLC (0.23%), Hennion & Walsh Asset Management Inc. (0.20%), Northern Trust Corp (0.16%), Yakira Capital Management Inc. (0.10%) and UBS Group AG (0.04%). Insiders that own company stock include Carl Goldfischer, David M Mott, Jeffery Kutok, Joseph Beaulieu, Matthew Ros, Pablo G Legorreta, Paolo Tombesi, Robert B Bazemore, Robert B Bazemore and Shefali Agarwal.
View institutional ownership trends
.

How do I buy shares of Epizyme?

Shares of EPZM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Epizyme's stock price today?

One share of EPZM stock can currently be purchased for approximately $1.47.

How much money does Epizyme make?

Epizyme (NASDAQ:EPZM) has a market capitalization of $247.50 million and generates $37.43 million in revenue each year. The biopharmaceutical company earns $-251,120,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis.

How many employees does Epizyme have?

The company employs 250 workers across the globe.

How can I contact Epizyme?

Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The official website for the company is www.epizyme.com. The biopharmaceutical company can be reached via phone at (617) 229-5872, via email at monique@thrustsc.com, or via fax at 617-349-0707.

This page (NASDAQ:EPZM) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.